A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

NCT07463183 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Colitis Ulcerative
Ulcerative Colitis

Interventions

DRUG: MK-8690
OTHER: Placebo

Sponsor

Merck Sharp & Dohme LLC